Longitudinal Association Between Baseline CSF GFAP Levels and Clinical Progression in Parkinson’s Disease A PPMI Study
Objective: To investigate whether baseline cerebrospinal fluid (CSF) glial fibrillary acidic protein (GFAP) levels predict changes in cognitive performance (MOCA) and motor severity (UPDRS) over…Evidence of Systemic and Neuro-Inflammation in Progressive Supranuclear Palsy: Insight from an Imaging-Inflammation Study
Objective: To investigate the role of Th17 pathway in systemic and central inflammation in PSP and to identify signatures of inflammation-induced neurodegeneration in PSP. Background:…Differential Microglial Activation and p-Ser129 Alpha-Synuclein Induction by Neurotropic and Non-Neurotropic Influenza A Virus Strains
Objective: To compare the innate immune responses and neurodegenerative marker induction in human microglia following infection with neurotropic vs. non-neurotropic Influenza A virus (IAV) under…Molecular Profiling of Brain-Derived Extracellular Vesicles and Fluid Biomarkers in Parkinsonism: Distinct Signatures and Clinical Correlates in Progressive Supranuclear Palsy
Objective: (1) To validate serum-based enrichment of neuronal (L1CAM+) and microglial (TMEM119+) EVs in PSP; (2) to characterize α-synuclein, tau, and inflammatory/autophagic mediators in EVs…Targeting the NLRP3 Inflammasome by PD180970 Based on Differential Susceptibility to MPTP
Objective: To delineate the role of NLRP3 Inflammasome activation to differential vulnerability in PD and to assess the therapeutic efficacy of PD180970 in targeting this…Characterising immune changes in the nose in Parkinson’s disease
Objective: To characterise the profile of innate immune cells in the nasal cavity in people with Parkinson’s disease (PD) versus controls. Background: Neuroinflammation provides novel…Plasma Fibrinogen Associates with Dopaminergic Neurodegeneration Independent of Peripheral Inflammation in drug-naïve Parkinson’s Disease
Objective: To investigate the association between plasma fibrinogen (Fib) levels, clinical features, and nigrostriatal dopaminergic neurodegeneration in drug-naïve patients with Parkinson’s disease (PD). Background: Fib…Multi-Modal Profiling of Peripheral and Central Nervous System T Cells Identifies Cytotoxic α-Synuclein-Reactive Immunity in Multiple System Atrophy
Objective: To define α-synuclein-specific peripheral T cell responses in multiple system atrophy (MSA) in comparison with parkinson’s disease (PD) and healthy controls (HC), and to…Association of IL-6 and Lp(a) with Incidental Parkinson’s Disease Risk and Motor Severity After Stroke: A Prospective Cohort Study
Objective: To investigate whether inflammatory and lipid-related biomarkers (IL-6 and Lipoprotein(a) [Lp(a)]) are associated with the risk of developing Parkinson's disease (PD) and motor severity…Intestinal Dysbiosis in Parkinson’s Disease: Mechanisms, Clinical Implications, and Therapeutic Perspectives (2015–2025)
Objective: This narrative review aims to consolidate research published from 2015 to 2025 regarding abnormalities in gut microbiota in patients with Parkinson’s disease, emphasizing potential…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 28
- Next Page »